Literature DB >> 22315256

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Gordon H Guyatt1, Susan L Norris2, Sam Schulman3, Jack Hirsh4, Mark H Eckman5, Elie A Akl6, Mark Crowther4, Per Olav Vandvik7, John W Eikelboom4, Marian S McDonagh2, Sandra Zelman Lewis8, David D Gutterman9, Deborah J Cook3, Holger J Schünemann3.   

Abstract

BACKGROUND: To develop the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines (AT9), the American College of Chest Physicians (ACCP) assembled a panel of clinical experts, information scientists, decision scientists, and systematic review and guideline methodologists.
METHODS: Clinical areas were designated as articles, and a methodologist without important intellectual or financial conflicts of interest led a panel for each article. Only panel members without significant conflicts of interest participated in making recommendations. Panelists specified the population, intervention and alternative, and outcomes for each clinical question and defined criteria for eligible studies. Panelists and an independent evidence-based practice center executed systematic searches for relevant studies and evaluated the evidence, and where resources and evidence permitted, they created standardized tables that present the quality of the evidence and key results in a transparent fashion.
RESULTS: One or more recommendations relate to each specific clinical question, and each recommendation is clearly linked to the underlying body of evidence. Judgments regarding the quality of evidence and strength of recommendations were based on approaches developed by the Grades of Recommendations, Assessment, Development, and Evaluation Working Group. Panel members constructed scenarios describing relevant health states and rated the disutility associated with these states based on an additional systematic review of evidence regarding patient values and preferences for antithrombotic therapy. These ratings guided value and preference decisions underlying the recommendations. Each topic panel identified questions in which resource allocation issues were particularly important and, for these issues, experts in economic analysis provided additional searches and guidance.
CONCLUSIONS: AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence, an explicit process for translating the evidence into recommendations, disclosure of financial as well as intellectual conflicts of interest followed by management of disclosed conflicts, and extensive peer review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315256      PMCID: PMC3278053          DOI: 10.1378/chest.11-2288

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  35 in total

Review 1.  Validity of composite end points in clinical trials.

Authors:  Victor M Montori; Gaietà Permanyer-Miralda; Ignacio Ferreira-González; Jason W Busse; Valeria Pacheco-Huergo; Dianne Bryant; Jordi Alonso; Elie A Akl; Antònia Domingo-Salvany; Edward Mills; Ping Wu; Holger J Schünemann; Roman Jaeschke; Gordon H Guyatt
Journal:  BMJ       Date:  2005-03-12

2.  Agreement among reviewers of review articles.

Authors:  A D Oxman; G H Guyatt; J Singer; C H Goldsmith; B G Hutchison; R A Milner; D L Streiner
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

Review 3.  Incorporating considerations of resources use into grading recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; Roman Jaeschke; Mark Helfand; Alessandro Liberati; Gunn E Vist; Holger J Schünemann
Journal:  BMJ       Date:  2008-05-24

4.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

5.  Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses.

Authors:  Toshiaki A Furukawa; Gordon H Guyatt; Lauren E Griffith
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

Review 6.  A clinician's guide to cost-effectiveness analysis.

Authors:  A S Detsky; I G Naglie
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

7.  Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.

Authors:  N Lubenow; P Eichler; T Lietz; A Greinacher
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

8.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Fred Leya; Marcie J Hursting; John G Kelton
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

9.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

10.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector.

Authors:  Raymond Hutubessy; Dan Chisholm; Tessa Tan-Torres Edejer
Journal:  Cost Eff Resour Alloc       Date:  2003-12-19
View more
  72 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; Holger J Schünemann; David D Gutterman; Sandra Zelman Lewis
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

5.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 8.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 9.  Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Authors:  Jonathan Stone; Patrick Hangge; Hassan Albadawi; Alex Wallace; Fadi Shamoun; M Grace Knuttien; Sailendra Naidu; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.

Authors:  Charlotte H So; Mark H Eckman
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.